AntriaBio

AntriaBio is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
Company Growth (employees)
Type
Public
HQ
Louisville, US
Founded
2010
Size (employees)
19 (est)
AntriaBio was founded in 2010 and is headquartered in Louisville, US

AntriaBio Office Locations

AntriaBio has an office in Louisville
Louisville, US (HQ)
1450 Infinite Dr

AntriaBio Data and Metrics

AntriaBio Financial Metrics

AntriaBio's revenue was reported to be $5.3 k in Q3, 2017
USD

Revenue (Q3, 2017)

5.3 k

Net income (Q3, 2017)

(14.1 m)

EBIT (Q3, 2017)

(5.4 m)

Market capitalization (20-Jul-2017)

57.2 m

Closing share price (20-Jul-2017)

1.1

Cash (31-Mar-2017)

4.4 m
AntriaBio's current market capitalization is $57.2 m.
USDFY, 2014FY, 2015FY, 2016

Sales and marketing expense

4.4 m

R&D expense

9.4 m

General and administrative expense

909.7 k

Operating expense total

5.2 m10.7 m15 m

EBIT

(5.2 m)(10.7 m)(15 m)

Interest expense

(5 k)

Interest income

965

Net Income

(9.7 m)(11.4 m)(14.9 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

5.3 k

Sales and marketing expense

1 m678.6 k628.3 k865.2 k1.1 m1.2 m1.3 m1.9 m1.9 m

R&D expense

112.6 k1.6 m1.3 m2 m2.5 m2.3 m2.5 m3.1 m

General and administrative expense

164.6 k183.9 k87 k205.2 k198.5 k302.7 k256.6 k301.5 k382.5 k

Operating expense total

1.3 m2.4 m2 m3 m3.9 m3.8 m4 m5.3 m2.2 m

EBIT

(2.2 m)(3.1 m)(2.3 m)(3.3 m)(4.1 m)(3.7 m)(3.8 m)(4.9 m)(5.4 m)

EBIT margin, %

(101596%)

Interest expense

(500)(2.3 k)(2.1 k)(1.6 k)(1.4 k)(1.1 k)(1.6 k)

Interest income

1.7 k1.3 k1.1 k7711931

Net Income

(2.2 m)(5.2 m)(8.3 m)(3.3 m)(7.4 m)(11.1 m)(3.8 m)(8.7 m)(14.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

5.9 m5.3 m4.1 m

Accounts Receivable

8.8 m

Inventories

289.6 k67.2 k

Current Assets

6.3 m6.1 m4.5 m

Total Assets

7.4 m11.3 m10.9 m

Accounts Payable

460.3 k1.4 m1.5 m

Total Debt

60 k

Current Liabilities

964 k1.7 m1.7 m

Non-Current Liabilities

33.9 k503.6 k400 k

Total Liabilities

997.9 k2.2 m2.1 m

Additional Paid-in Capital

24.1 m38.1 m52.8 m

Retained Earnings

(17.7 m)(29.1 m)(44 m)

Total Equity

6.4 m9.1 m8.8 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.2 x1.2 x1.2 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

4.3 m8.6 m8.2 m2.4 m1.7 m1.7 m3.4 m3.6 m4.4 m

Inventories

301.9 k76.1 k92.4 k186.8 k

Current Assets

4.7 m8.7 m8.9 m3.1 m1.8 m2 m3.7 m3.8 m4.8 m

Total Assets

6.3 m10.7 m12.1 m9.2 m8.5 m8.8 m10.1 m9.9 m10.8 m

Accounts Payable

320.1 k874.7 k1.3 m1.7 m2.2 m2.2 m1.3 m1.5 m1.9 m

Current Liabilities

892.9 k2.4 m1.8 m2 m2.5 m2.4 m1.5 m1.7 m2 m

Non-Current Liabilities

354.8 k534.7 k553.4 k453.6 k460.8 k431.3 k367.8 k335.6 k314.7 k

Additional Paid-in Capital

25 m30.7 m35.8 m39.1 m40.2 m41.3 m56 m60.6 m66.5 m

Retained Earnings

(20 m)(22.9 m)(26.1 m)(32.4 m)(36.5 m)(40.2 m)(47.9 m)(52.7 m)(58.1 m)

Total Equity

5 m7.8 m9.7 m6.8 m3.8 m1.1 m8.2 m7.9 m8.5 m

Financial Leverage

1.2 x1.4 x1.2 x1.4 x2.3 x7.9 x1.2 x1.3 x1.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(9.7 m)(11.4 m)(14.9 m)

Depreciation and Amortization

7.8 k128.9 k744 k

Inventories

222.4 k

Cash From Operating Activities

(3.2 m)(7.1 m)(10.5 m)

Purchases of PP&E

(70 k)(3.1 m)(2.1 m)

Cash From Investing Activities

(830.2 k)(3.6 m)(1.5 m)

Cash From Financing Activities

9.9 m10 m10.7 m

Interest Paid

15.7 k
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(2.2 m)(5.2 m)(8.3 m)(3.3 m)(7.4 m)(11.1 m)(3.8 m)(8.7 m)(14.1 m)

Depreciation and Amortization

27.4 k57.9 k91 k70.3 k220.5 k476.9 k268.4 k546.4 k829.3 k

Inventories

213.5 k197.2 k

Cash From Operating Activities

(1.5 m)(3.2 m)(5.1 m)(2.5 m)(4.8 m)(7.3 m)(3 m)(6.1 m)(9.7 m)

Purchases of PP&E

(168 k)(266 k)(875 k)(576.3 k)(1.3 m)(1.8 m)(127 k)(272.6 k)(300.3 k)

Cash From Investing Activities

(168 k)(321 k)(1.4 m)(388.9 k)(619.9 k)(1.1 m)(61 k)(85.1 k)(112.8 k)

Cash From Financing Activities

6.2 m8.8 m(23.1 k)1.8 m4.9 m2.3 m5.7 m10.2 m
USDY, 2017

Revenue/Employee

279.3

Financial Leverage

1.3 x

AntriaBio Market Value History

Traffic Overview of AntriaBio

AntriaBio Online and Social Media Presence

AntriaBio Company Life and Culture

You may also be interested in